Online inquiry

IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6626MR)

This product GTTS-WQ6626MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6626MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6599MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ6087MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ15574MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ2487MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ15471MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ14653MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ14335MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ4320MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIVV009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW